{Reference Type}: Journal Article
{Title}: Identification of potential pharmacological chaperones that selectively stabilize mutated Aspartoacylases in Canavan disease.
{Author}: Poddar NK;Wijayasinghe YS;Viola RE;
{Journal}: Biochim Biophys Acta Proteins Proteom
{Volume}: 1872
{Issue}: 6
{Year}: 2024 Aug 9
{Factor}: 4.125
{DOI}: 10.1016/j.bbapap.2024.141043
{Abstract}: Canavan disease is caused by mutations in the ASPA gene, leading to diminished catalytic activity of aspartoacylase in the brain. Clinical missense mutations are found throughout the enzyme structure, with many of these mutated enzymes having not only decreased activity but also compromised stability. High-throughput screening of a small molecule library has identified several compounds that significantly increase the thermal stability of the E285A mutant enzyme, the most predominant clinical mutation in Canavan disease, while having a negligible effect on the native enzyme. Based on the initial successes, some structural analogs of these initial hits were selected for further examination. Glutathione, NAAG and patulin were each confirmed to be competitive inhibitors, indicating the binding of these compounds at the dimer interface or near the active site of the E285A enzyme. The experimental results were theoretically examined with the help of the docking analysis method. The structure activity-guided optimization of these compounds can potentially lead to potential pharmacological chaperones that could alleviate the detrimental effect of ASPA mutations in Canavan patients.